Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 12/20 | 1.00 |
| ▸ | CYP11B1 | P15538 | 10/20 | 0.59 |
| ▸ | CYP11B2 | P19099 | 10/20 | 0.59 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.59 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.59 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.53 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.53 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23905177 | 0.94 | CYP17A1 (0.89) | CYP17A1CYP11B1CYP11B2CYP19A1CYP3A4 | |
| SCHEMBL3104632 | 0.85 | CYP17A1 (0.72) | CYP17A1HDAC1HDAC6MKNK1MKNK2 | |
| SCHEMBL27536266 | 0.83 | CYP17A1 (0.71) | CYP17A1CYP3A4PLA2G10PLA2G2AHDAC1 | |
| Hydrochloric Acid SCHEMBL4442122 | 0.83 | CYP17A1 (0.70) | CYP17A1HDAC1HDAC6MKNK1MKNK2 | |
| SCHEMBL7134591 | 0.82 | PLA2G10 (0.83) | CYP17A1CYP3A4PLA2G10PLA2G2ATSHR | |
| SCHEMBL15853634 | 0.81 | CYP17A1 (0.68) | CYP17A1CYP3A4TSHR | |
| SCHEMBL2987890 | 0.80 | CYP17A1 (0.66) | CYP17A1PLA2G10PLA2G2AHDAC1HDAC6 | |
| SCHEMBL27193227 | 0.79 | CYP17A1 (0.66) | CYP17A1CYP11B1CYP11B2CYP19A1CYP3A4 | |
| SCHEMBL27193239 | 0.78 | CYP17A1 (0.62) | CYP17A1PLA2G10PLA2G2AHDAC1HDAC6 | |
| SCHEMBL18906031 | 0.77 | HDAC1 (0.65) | CYP17A1HDAC1HDAC6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3365819-B1 | PHARMACOPHORES, COMPOUNDS AND METHODS HAVING APPLICATION IN THE TREATMENT OF CANCER THROUGH INHIBITION OF CYP17A1 AND CYP19A1 | MANGOSUTHU UNIV OF TECHNOLOGY (ZA) | 2023-06-07 | — | — | EP | disclosed |
| EP-3365330-B1 | PHARMACOPHORES, COMPOUNDS AND METHODS HAVING APPLICATION IN THE TREATMENT OF CANCER THROUGH INHIBITION OF CYP17A1 AND CYP19A1 | MANGOSUTHU UNIV OF TECHNOLOGY (ZA) | 2023-06-07 | — | — | EP | disclosed |
| US-11548860-B2 | Pharmacophores, compounds and methods having application in the treatment of cancer through inhibition of CYP17A1 and CYP19A1 | MANGOSUTHU UNIVERSITY OF TECHNOLOGY (ZA) | 2023-01-10 | — | — | US | disclosed |
| US-20200247764-A1 | PHARMACOPHORES, COMPOUNDS AND METHODS HAVING APPLICATION IN THE TREATMENT OF CANCER THROUGH INHIBITION OF CYP17A1 AND CYP19A1 | MANGOSUTHU UNIVERSITY TECHNOLOGY (ZA) | 2020-08-06 | — | — | US | disclosed |
| US-20200247794-A1 | PHARMACOPHORES, COMPOUNDS AND METHODS HAVING APPLICATION IN THE TREATMENT OF CANCER THROUGH INHIBITION OF CYP17A1 AND CYP19A1 | MANGOSUTHU UNIVERSITY TECHNOLOGY (ZA) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247794-A1 | PHARMACOPHORES, COMPOUNDS AND METHODS HAVING APPLICATION IN THE TREATMENT OF CANCER THROUGH INHIBITION OF CYP17A1 AND CYP19A1 | CYP19A1, CYP26A1, CYP21A2 | CYP17A1 5/4885CYP11B1 7/4885CYP11B2 21/4885 |
| US-20200247764-A1 | PHARMACOPHORES, COMPOUNDS AND METHODS HAVING APPLICATION IN THE TREATMENT OF CANCER THROUGH INHIBITION OF CYP17A1 AND CYP19A1 | CYP19A1, CYP26A1, CYP21A2 | CYP17A1 10/4885CYP11B1 16/4885CYP11B2 32/4885 |
| US-11548860-B2 | Pharmacophores, compounds and methods having application in the treatment of cancer through inhibition of CYP17A1 and CYP19A1 | CYP19A1, CYP26A1, CYP21A2 | CYP17A1 10/4885CYP11B1 16/4885CYP11B2 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.